SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001819790-23-000004
Filing Date
2023-03-13
Accepted
2023-03-13 16:07:30
Documents
14
Period of Report
2023-03-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K tars-20230313.htm   iXBRL 8-K 34632
2 EX-99.1 exhibit991tarsus3132023pre.htm EX-99.1 99626
6 GRAPHIC picture1a.jpg GRAPHIC 5866
  Complete submission text file 0001819790-23-000004.txt   293651

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT tars-20230313.xsd EX-101.SCH 1890
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT tars-20230313_lab.xml EX-101.LAB 24831
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT tars-20230313_pre.xml EX-101.PRE 13035
8 EXTRACTED XBRL INSTANCE DOCUMENT tars-20230313_htm.xml XML 11333
Mailing Address 15440 LAGUNA CANYON ROAD IRVINE CA 92618
Business Address 15440 LAGUNA CANYON ROAD IRVINE CA 92618 (949) 409-9820
Tarsus Pharmaceuticals, Inc. (Filer) CIK: 0001819790 (see all company filings)

IRS No.: 814717861 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39614 | Film No.: 23727349
SIC: 2836 Biological Products, (No Diagnostic Substances)